1. Home
  2. MDV vs HURA Comparison

MDV vs HURA Comparison

Compare MDV & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Modiv Industrial Inc. Class C

MDV

Modiv Industrial Inc. Class C

HOLD

Current Price

$17.53

Market Cap

187.5M

ML Signal

HOLD

Logo TuHURA Biosciences Inc.

HURA

TuHURA Biosciences Inc.

HOLD

Current Price

$2.34

Market Cap

160.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDV
HURA
Founded
2015
2009
Country
United States
United States
Employees
9
22
Industry
Transportation Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
187.5M
160.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MDV
HURA
Price
$17.53
$2.34
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
2
Target Price
$18.00
$9.50
AVG Volume (30 Days)
68.0K
718.2K
Earning Date
05-08-2026
05-15-2026
Dividend Yield
7.50%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8.56
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.80
$0.41
52 Week High
$18.83
$3.90

Technical Indicators

Market Signals
Indicator
MDV
HURA
Relative Strength Index (RSI) 46.88 50.51
Support Level $17.19 $2.09
Resistance Level $18.75 $2.71
Average True Range (ATR) 0.38 0.22
MACD -0.05 -0.01
Stochastic Oscillator 45.45 36.43

Price Performance

Historical Comparison
MDV
HURA

About MDV Modiv Industrial Inc. Class C

Modiv Industrial Inc is a pioneer in the direct-to-consumer commercial real estate product industry. It provides individual investors access to real estate and real estate-related investments designed to provide both income and long-term growth. The company has invested in single-tenant income-producing properties. Its current business consists of owning, managing, operating, leasing, acquiring, investing in, and disposing of commercial real estate assets utilized for industrial manufacturing, as well as a few non-core assets. All of the company's consolidated revenues are derived from the company's consolidated real estate properties.

About HURA TuHURA Biosciences Inc.

TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.

Share on Social Networks: